Grace Therapeutics, Inc. (GRCE)
$2.13-$0.04 (-1.85%) Today
George KottayilGrace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 11,608 | $24K |
6 Form 4 filings on record, the earliest from May 9, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 11,608 | $2.09 | $24K | |
 Vimal Kavuru | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| George Kottayil | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Edward Neugeboren | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| A. Brian Davis | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| A. Brian Davis | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - |
Grace Therapeutics, Inc. (GRCE) had 1 insider filing in the last 90 days, with the most recent on 2026-08-19. The full record for GRCE runs to 6 Form 4 filings, the earliest from 2025-05-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of GRCE was filed in the last 90 days, totaling $24K.
No insider sales of GRCE were filed in the last 90 days.
This page tracks GRCE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GRCE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
